Table 1.

Summary of cases of AKI reported with vemurafenib

Publication	Total number of patients	Time of onset of renal dysfunction after starting vemurafenib	Cancer	Mean age (years)	Males/females	Pathology reported	Outcomes
Uthurriague et al. [16]	15	After 1 month	Melanoma	Not reported	10/6	None	Decrease in renal function persisted for 3 months. In the patients with the longest follow-up (8 months), CKD persisted
Regnier-Rosencher et al. [17]	4	After 1–2 weeks	Melanoma	76	4/0	None	See Table 2
Launay-Vacher et al. [18]	8	50% after 1–2 months; 50% after 1–2 weeks	Melanoma	66	6/2	ATN (one biopsy)	See Table 2

ATN, acute tubular necrosis.